PharmiWeb.com - Global Pharma News & Resources
27-Sep-2018

Ocugen to Present at Two Upcoming Investor Conferences

MALVERN, Pa., Sept. 26, 2018 /PRNewswire/ -- Ocugen, Inc., a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases, today announced that Shankar Musunuri, Ph.D., Chairman, CEO and Co-Founder of Ocugen, will give presentations at two upcoming investor conferences. Dr. Musunuri will present at the Cantor Fitzgerald Global Healthcare Conference, held October 1-3, 2018, and at the Chardan Genetic Medicines Conference, held October 9, 2018. Both conferences will take place in New York City.

Cantor Fitzgerald Global Healthcare Conference:
Date: Tuesday, October 2, 2018
Time: 10:55am ET
Location: Track 6 – Rockefeller Suite; Intercontinental New York Barclay Hotel

Chardan Genetic Medicines Conference:
Date: Tuesday, October 9, 2018
Time: 4:15pm ET
Location: Embassy Room; Westin Grand Central Hotel

About Ocugen, Inc.
Ocugen, Inc. is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The Company's lead clinical candidate (OCU300) is currently in Phase 3 for treating ocular graft versus host disease (oGVHD) and is the first and only therapeutic with orphan drug designation for oGVHD, providing certain regulatory and economic benefits. The Company's second lead candidate for treating dry eye disease (OCU310) is also expected to enter pivotal clinical trials in 2018. Both OCU300 and OCU310 leverage Ocugen's patented OcuNanoE – Ocugen's ONE Platform™ technology to enhance the efficacy of topical ophthalmic therapeutics. Ocugen is also developing novel biologic therapies for retinitis pigmentosa (OCU100) and wet AMD (OCU200), as well as a groundbreaking modifier gene therapy platform with potential to address a broad spectrum of inherited retinal disorders (OCU400). For more information, please visit www.ocugen.com.

Contact:
Ocugen, Inc.
Kelly Beck
kelly.beck@ocugen.com
+1 484-328-4698

Editor Details

Related Links

Last Updated: 27-Sep-2018